Close
Xylem
Novotech

News

Ardena’s Nanomedicines Facility Marks โ‚ฌ20 Million Expansion with first GMP approval

Ardena, a leading Contract Development and Manufacturing Organization (CDMO) specializing in bringing molecules to clinic, has received Good Manufacturing Practice (GMP) approval from the Dutch Healthcare Authority for its new analytical laboratories in its expanded nanomedicines facility. The facility includes...

Cell & Gene Therapies: FDA Regulatory Considerations In 2024

The fact is that most in the biotech industry know that cell and gene therapies- CGT are regulated across the U.S. as biological products by the FDAโ€™s Center for Biologics Research and Evaluation- BER and need approval of a...

Can Clinical Research Spectrum Make The Most of Gene Therapy

It is a well-established fact that gene therapy research happens to be booming. Since the U.S. Food and Drug Administration- FDA issued its first approval when it comes to gene therapy in 2017, oncology researchers have gone on to...

US Enacts Biosecurity Law Blocking Chinese Bio Company Deals

In March 2024, one of the biosecurity laws restricting transactions with Chinese bio companies happened to pass the U.S. Congress, and now the global contract development and production- CDMO companies happen to be trying to secure production facilities within...

Market Trends: Biologics Clinical Manufacturing CDMO Service

In the ever-changing pharma and biologics sector, the Biologics Clinical Manufacturing CDMO Service market has gone on to emerge as quite a prominent player in the global economy, thereby going ahead and also exhibiting noteworthy growth and at the...

CDMOs Offering Unique Options To Meet Cold Chain Demands

It is worth noting that the Cell and gene therapies- CGTs have gone on to show immense promise when it comes to treating diverse conditions, right from cancer to neurodegenerative diseases. But, alongside their potential perks, they go on...

Latest real-world evidence presented at WCO-IOF-ESCEO assesses how EVENITY can help to close the treatment gap in osteoporosis

UCB, a global biopharmaceutical company announced key findings from the first retrospective patient cohort study in Denmark to observe the characteristics of patients selected for romosozumab treatment in routine clinical practice. The data were presented as a poster presentation...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป